Azza Ayad, Reham Khedr, Asmaa Hamoda, Nahla Elnabarawy, Elhamy Rifky, Tamer Diab, Eman El Desouky, Leslie Lehmann, Alaa Elhaddad
{"title":"儿科非霍奇金淋巴瘤幸存者的生活质量和后期治疗效果：一项单一机构研究的启示。","authors":"Azza Ayad, Reham Khedr, Asmaa Hamoda, Nahla Elnabarawy, Elhamy Rifky, Tamer Diab, Eman El Desouky, Leslie Lehmann, Alaa Elhaddad","doi":"10.1002/pbc.31357","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and aim</h3>\n \n <p>The survival outcomes of pediatric patients with mature B-non-Hodgkin lymphoma (NHL) have improved due to advances in treatment. We aimed to assess the frequency and severity of late effects and their impact on quality of life among pediatric NHL survivors.</p>\n </section>\n \n <section>\n \n <h3> Patients and methods</h3>\n \n <p>This retrospective study included patients diagnosed with mature B-NHL at Children's Cancer Hospital of Egypt (CCHE) 57357 from January 2012 through December 2015. Patients received treatment according to the modified LMB 96 protocol. The minimum follow-up period was 5 years. Assessments for toxicity and quality of life were conducted at regular intervals during and after treatment. Patients were assessed for toxicity including pulmonary dysfunction, cardiac dysfunction, lipid profile abnormalities, endocrine dysfunction (thyroid function, vitamin D levels, growth curves), and cognitive function (intelligence quotient [IQ] level using Stanford–Binet Intelligence Scales—5th Edition, and quality of life (QoL) assessment (PedsQoL).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 273 patients were eligible, and 206 were evaluable. Median age was 5.45 (range: 2.4–18), with a male-to-female ratio 4:1. Pulmonary function abnormalities were detected in 119/203 (58.6%); most had mild dysfunction (72/119, 60.5%), while 17% had severe dysfunction. Cardiac toxicity occurred in 10% of the patients (<i>n</i> = 20). IQ testing showed that 52 patients had a low average IQ score, while 151 patients had either average or above average scores. The total mean QoL score was 99 ± 0.058 classified as “satisfactory.” However, significant impairment of the physical domain of quality of life was observed among group C patients compared to A/B (<i>p</i> = .033), older age at diagnosis (<i>p</i> = .042), and those with pulmonary dysfunction (<i>p</i> < .001). Total score of quality of life was significantly impaired among patients with pulmonary dysfunction (<i>p</i> = .009), likewise older age at diagnosis (<i>p</i> = .017) and those with low average IQ scores (<i>p</i> = .033).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Childhood mature B-NHL survivors are at significant risk for late effects; pulmonary dysfunction and low average IQ that can subsequently impact QoL</p>\n </section>\n </div>","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":"71 12","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Quality of life and late therapy effects in pediatric non-Hodgkin lymphoma survivors: Insights from a single-institution study\",\"authors\":\"Azza Ayad, Reham Khedr, Asmaa Hamoda, Nahla Elnabarawy, Elhamy Rifky, Tamer Diab, Eman El Desouky, Leslie Lehmann, Alaa Elhaddad\",\"doi\":\"10.1002/pbc.31357\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background and aim</h3>\\n \\n <p>The survival outcomes of pediatric patients with mature B-non-Hodgkin lymphoma (NHL) have improved due to advances in treatment. We aimed to assess the frequency and severity of late effects and their impact on quality of life among pediatric NHL survivors.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Patients and methods</h3>\\n \\n <p>This retrospective study included patients diagnosed with mature B-NHL at Children's Cancer Hospital of Egypt (CCHE) 57357 from January 2012 through December 2015. Patients received treatment according to the modified LMB 96 protocol. The minimum follow-up period was 5 years. Assessments for toxicity and quality of life were conducted at regular intervals during and after treatment. Patients were assessed for toxicity including pulmonary dysfunction, cardiac dysfunction, lipid profile abnormalities, endocrine dysfunction (thyroid function, vitamin D levels, growth curves), and cognitive function (intelligence quotient [IQ] level using Stanford–Binet Intelligence Scales—5th Edition, and quality of life (QoL) assessment (PedsQoL).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A total of 273 patients were eligible, and 206 were evaluable. Median age was 5.45 (range: 2.4–18), with a male-to-female ratio 4:1. Pulmonary function abnormalities were detected in 119/203 (58.6%); most had mild dysfunction (72/119, 60.5%), while 17% had severe dysfunction. Cardiac toxicity occurred in 10% of the patients (<i>n</i> = 20). IQ testing showed that 52 patients had a low average IQ score, while 151 patients had either average or above average scores. The total mean QoL score was 99 ± 0.058 classified as “satisfactory.” However, significant impairment of the physical domain of quality of life was observed among group C patients compared to A/B (<i>p</i> = .033), older age at diagnosis (<i>p</i> = .042), and those with pulmonary dysfunction (<i>p</i> < .001). Total score of quality of life was significantly impaired among patients with pulmonary dysfunction (<i>p</i> = .009), likewise older age at diagnosis (<i>p</i> = .017) and those with low average IQ scores (<i>p</i> = .033).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Childhood mature B-NHL survivors are at significant risk for late effects; pulmonary dysfunction and low average IQ that can subsequently impact QoL</p>\\n </section>\\n </div>\",\"PeriodicalId\":19822,\"journal\":{\"name\":\"Pediatric Blood & Cancer\",\"volume\":\"71 12\",\"pages\":\"\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-10-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Blood & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pbc.31357\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pbc.31357","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Quality of life and late therapy effects in pediatric non-Hodgkin lymphoma survivors: Insights from a single-institution study
Background and aim
The survival outcomes of pediatric patients with mature B-non-Hodgkin lymphoma (NHL) have improved due to advances in treatment. We aimed to assess the frequency and severity of late effects and their impact on quality of life among pediatric NHL survivors.
Patients and methods
This retrospective study included patients diagnosed with mature B-NHL at Children's Cancer Hospital of Egypt (CCHE) 57357 from January 2012 through December 2015. Patients received treatment according to the modified LMB 96 protocol. The minimum follow-up period was 5 years. Assessments for toxicity and quality of life were conducted at regular intervals during and after treatment. Patients were assessed for toxicity including pulmonary dysfunction, cardiac dysfunction, lipid profile abnormalities, endocrine dysfunction (thyroid function, vitamin D levels, growth curves), and cognitive function (intelligence quotient [IQ] level using Stanford–Binet Intelligence Scales—5th Edition, and quality of life (QoL) assessment (PedsQoL).
Results
A total of 273 patients were eligible, and 206 were evaluable. Median age was 5.45 (range: 2.4–18), with a male-to-female ratio 4:1. Pulmonary function abnormalities were detected in 119/203 (58.6%); most had mild dysfunction (72/119, 60.5%), while 17% had severe dysfunction. Cardiac toxicity occurred in 10% of the patients (n = 20). IQ testing showed that 52 patients had a low average IQ score, while 151 patients had either average or above average scores. The total mean QoL score was 99 ± 0.058 classified as “satisfactory.” However, significant impairment of the physical domain of quality of life was observed among group C patients compared to A/B (p = .033), older age at diagnosis (p = .042), and those with pulmonary dysfunction (p < .001). Total score of quality of life was significantly impaired among patients with pulmonary dysfunction (p = .009), likewise older age at diagnosis (p = .017) and those with low average IQ scores (p = .033).
Conclusion
Childhood mature B-NHL survivors are at significant risk for late effects; pulmonary dysfunction and low average IQ that can subsequently impact QoL
期刊介绍：
Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
